Julia Tchou, MD PhD (Presenter;Submitter) – University of Pennsylvannia; INTRODUCTION: Immune checkpoint inhibition (ICI) is currently only used in combination with chemotherapy in breast cancer

(Dallas—March 10, 2022, 5:11 p.m.) — While the incidence level of most cancers has declined over the last decade, anal squamous cell cancer (ASCC), an

(Dallas—March 11, 2022, 10:11 a.m.) — The use of pegulicianine fluorescence guided surgery (pFGS) for identifying residual cancer in the tumor bed of patients undergoing

(Dallas, March 11, 2022; 1:11 p.m.) — Gastrointestinal stromal tumor is the most common human sarcoma and is typically driven by a single mutation in

(Dallas—March 12, 2022, 8:29 a.m.) — Compared to traditional Medicare, Medicare Advantage enrollment was associated with a lower probability of surgery at high volume center

(Dallas—March 12, 2022, 8:11 a.m.)– A survey of Canadian patients with cancer found that cancer follow-up led by primary care providers is safe and effective compared to

(Dallas, March 12, 2022, 8:01 a.m.) — Researchers from Memorial Sloan Kettering Cancer developed a nomogram that can preoperatively identify patients at high risk of

(Dallas–March 10, 2022, 2:13 p.m.) — Black patients who had had elective pancreas, lung, colon, and rectal resection for cancer had higher mortality rates than

(Dallas –March 11, 2022 1:21 p.m.)–Both clinical and pathologic factors can be used to predict lymph node recurrence after sentinel lymph nodes yet the first post-operative ultrasound

(Dallas—March 11, 2022, 1:11 p.m.) — Completion lymph node dissection (CLND) for tumor-positive sentinel lymph node biopsy (SLNB) is no longer recommended routinely in the